A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL)

This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of autologous chimeric antigen receptor T (CAR-T) cells targeting CD19/CD22/BCMA in patients with relapsed or refractory B cell non-Hodgkin lymphoma.

Trial Details

NCT ID
NCT06446128
Phase
EARLY_PHASE1
Sponsor
Shanghai Cell Therapy Group Co.,Ltd
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • CD19/CD20/BCMA CAR T cells
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Patients who are diagnosed with relapsed/refractory B cell non-Hodgkin lymphoma , especially
  • Diffuse Large B Cell Lymphoma, not other specified (DLBCL,NOS),
  • Primary Mediastinal Large B Cell Lymphoma (PMBCL)
  • Transformation Follicular Lymphoma (TFL)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →